Business Wire

CA-ZYNGA

16.7.2020 15:02:09 CEST | Business Wire | Press release

Share
Zynga Appoints Noel Watson to Board of Directors

Zynga Inc. (Nasdaq:ZNGA), a global leader in interactive entertainment, today announced that Noel Watson, Chief Financial Officer at TrueCar Inc., joined the company's Board as an independent director. A skilled executive with a wealth of experience in building digital services and leading teams, Noel Watson becomes the ninth member of Zynga's Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005015/en/

“Noel brings to Zynga more than 20 years of successful financial and operating leadership,” said Frank Gibeau, Chief Executive Officer at Zynga. “His extensive experience with high growth digital services and strong track record with mergers and acquisitions will be powerful additions to our company. We are excited to welcome Noel to Zynga’s Board of Directors and Audit Committee.”

Mr. Watson joined TrueCar Inc., a leading automotive digital marketplace focused on creating the most innovative and efficient experience for car buyers, in 2019 as the company’s CFO, leading financial operations including accounting and investor relations. Prior to TrueCar, Mr. Watson held the position of Chief Accounting Officer at TripAdvisor Inc., the world’s largest travel platform with over 400 million unique monthly site visitors. He began his career as a certified public accountant at Arthur Andersen LLP and subsequently held management positions at Boston based technology firms ArrAy Inc. and Way Systems prior to joining TripAdvisor in 2006. Mr. Watson holds a bachelor’s degree in accounting from Bryant University.

“I am excited to be joining Zynga’s Board of Directors during this dynamic period of growth for the company in its mission to connect the world through games,” said Noel Watson. “With the increasing penetration and use of mobile phones, and the more than 2.5 billion people globally playing games by the end of 2020, Zynga is incredibly well positioned to be a force in digital entertainment, built around iconic brands and experiences that people love.”

“After months of conversation, I could not be more pleased that Noel Watson is joining Zynga’s Board of Directors,” said Ellen Siminoff, Director and Chair of the Nominating and Governance Committee at Zynga. “With more growth ahead for Zynga, Noel’s experience and perspective will be instrumental in our continued success. Noel brings with him a proven ability to lead and execute, and his point of view will be invaluable for our company.”

Zynga's distinguished Board members include Frank Gibeau, Regina Dugan, William "Bing" Gordon, Louis Lavigne Jr., Carol Mills, Mark Pincus, Janice Roberts, and Ellen Siminoff. On Zynga's Board, Mr. Watson will serve on the Audit Committee alongside members Louis Lavigne, Jr., Carol Mills, and Ellen Siminoff.

Editor’s Note:

Key art and photography assets available for use = https://bit.ly/ZyngaBODAnnouncement

About Zynga Inc.

Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR RacingTM , Empires & PuzzlesTM , Merge Dragons!TM , Merge Magic!TM , Toon Blast™, Toy Blast™, Words With FriendsTM and Zynga PokerTM . Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter , Instagram , Facebook or the Zynga blog .

Forward-Looking Statements

This press release contains forward-looking statements regarding our expectations related to growth in Zynga’s business and the mobile game industry. Forward-looking statements often include words such as “next,” “intend,” “will,” “anticipate,” “believe,” “ahead,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s web site at www.sec.gov .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye